Cellebrite DI Ltd. shares fell more than 30% after the company reported Q2 2026 results showing revenue and ARR (annual recurring revenue) growth below expectations. The company also cut its full-year ARR guidance to $550 million-$560 million from $567 million-$573 million, indicating weaker momentum in its recurring business than previously projected.